Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inhibitex to test antibody in premature babies
Enrollment in the trial, which began in late May 2004, was completed in less than 18 months. The trial is being conducted at 95 neonatal intensive care units
Enrollment in the trial, which began in late May 2004, was completed in less than 18 months. The trial is being conducted at 95 neonatal intensive care units
Age-related learning and memory decline in the brain has also been shown to be accompanied by inflammatory changes, typified by microglial activation. These changes are also accompanied and
Under terms of the agreement, Recordati will have the exclusive right to market and sell Labopharm’s product in the UK. Labopharm will provide Recordati with the finished packaged
The models should provide new insights into the processes that cause degeneration of the nervous system in patients with multiple system atrophy, but also as models in which
Ab68 is one of two antibodies comprising XTLbio’s lead hepatitis C drug candidate, XTL-6865. This pilot study was conducted in patients with hepatitis C following liver transplantation. Patients
In June of this year, Gilead delivered a notice of termination to Roche of the companies’ 1996 agreement relating to Tamiflu and the companies subsequently entered into arbitration.
Pfizer had been hoping to secure a key marketing advantage for Lipitor but although the trial demonstrated an 11% reduction in major coronary events in Lipitor patients compared
Recent analytical-study results were submitted to the FDA and cleared for incorporation into the analytical sensitivity section of the Xpect Flu A&B package insert. Testing was performed in
Although Thalomid is already prescribed off-label by doctors wishing to treat multiple myeloma (progressive blood cancer), Celgene is intent on acquiring official recognition for the indication. In response
To date, 31 patients have been treated across eight dose levels and are available for safety analysis. In the trial, XL647 was generally well tolerated with fatigue, nausea